Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03087448 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Ceritinib
DRUG: Trametinib

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]